

MINISTRY OF HEALTH & FAMILY WELFARE

Government of India

Through

**RITES Ltd., RITES Office Complex, Annexe Building,
Materials System Management Division, 4th floor, Plot No.144, Sector 44
Gurgaon-122003 (Haryana), India**

Minutes of Pre-Bid Conference

For

Supply of Anti TB Drugs

under

Revised National Tuberculosis control Programme

through

International Competitive Bidding

Bid Ref. No:

RITES/MSM/EPW/RNTCP/02/2014/WB

(PC-5, 6, 7, 8, 10, 11, 17, 23, 25, 26, 27, 28, 29, 32, 33, 35, 36, 37, 38, 39, 40, 42, 43, 45)

and

RITES/MSM/EPW/RNTCP/02/2014/DOM

(PC-5, 6, 7, 8, 10, 11, 23, 25, 26, 28, 29, 32, 35, 36, 37, 38, 39, 40, 43, 45)

Held on

July 1, 2014 at 14:00 Hrs (Local Time)

1. Followings RITES officials were present during the pre-bid meeting

1. Mr. V. Sudhakara Rao, GM/EPW/MSM, RITES Ltd
2. Mr P.V. Datta AM/MSM, RITES Ltd.
3. Mr Nitin Jain Engg/MSM, RITES Ltd.
4. Mr. R.L. Rastogi, Procurement Expert, RITES Ltd.

Followings Firms' representatives were present during the pre-bid meeting

1. Mr. J.B Pal, AGM Institution Sales, M/s Macleods Pharmaceuticals Ltd.
2. Mr Vinod Rawat, Manager Institution Sales, M/s Panacea Biotec Ltd.
3. Mr Onkar Nath Yadav, Officer, M/s Bio Medical Laboratories
4. Mr Bhupinder Singh, Manager, M/s Umedica Laboratories Pvt. Ltd.
5. Mr Mukul Jerath, DGM Global Inst. Business, M/s Lupin Ltd.
6. Mr Dilip Peswani, Manager Business Development, M/s Lupin Ltd.
7. Mr Arun Sharma, Agent, M/s Macleods Pharma Ltd.

2 Tenders have been invited through ICB from all the eligible bidders.

3. Initiating the discussion, Mr. V. Sudhakara Rao welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the

bidding documents and also to clarify any queries that the bidders may have regarding commercial or technical issues in the subject bidding documents.

4 Queries have been raised by the prospective bidders which are clarified as follows:-

S.No.	Query	Clarification
1	Can Lupin participate in the bidding for some product schedules by using a manufacturing facility which is not Lupin's own facility under an agreement with the manufacturer (either third party agreement or loan license agreement) as has been mentioned in IFB 7.1 (b) section in RITES/MSM/EPW/RNTCP/02/2014/WB	Supply arrangement with registered Loan Licence Agreements are legal & hence can be accepted.
2	With respect to the logo dimensions which have been fixed for all millboard boxes and 5 Ply shippers : We have had to in some case in the past reduce the size of the logo in order to be able to accommodate all the text which is required to be put on the label for box/ shipper. We had conveyed this and sought approval for this after the awarding of contract but it creates confusion as the inspectors who inspect would raise these points as irregularities. Please check if the dimension for the logo as a parameter can be fixed at the time of approval of artworks and that approval of artwork is used to compare with the final products by inspectors?	For change in logo dimensions, MoH&FW will give approval as and when required. However, the requisite information pertaining to any change in logo dimensions needs to be submitted well in advance to avoid any delay in delivery schedule. Refer Amendment 1
3	With respect to PC -39 : The product specifications mentions Moxifloxacin should be as per European Pharmacopoeia. Could you confirm if Moxifloxacin as per Indian Pharmacopoeia would be acceptable ? All other drugs for the different product schedules are following Indian Pharmacopoeia?	Tab Moxifloxacin – 400 mg (PC-39) as per Indian Pharmacopoeia is acceptable. However, all the quality standards of Moxifloxacin – 400 mg should conform to the requirements of the monograph given in Indian pharmacopoeia. Refer Amendment 1
4	In pyrazinamide tabs the shelf life provided is 60 months. We just want to understand if one can provide the shelf life of 36 months as it will increase the existing competition?	Deviation from Technical specification is not acceptable.

Meeting concluded with thanks to the participants for their active participation.

RITES Ltd.